目的 探討紅花逍遙片聯(lián)合雌二醇片/雌二醇地屈孕酮片復(fù)合包裝治療圍絕經(jīng)期綜合征的臨床效果。方法 選取2016年7月—2019年6月新鄉(xiāng)市中心醫(yī)院收治的100例圍絕經(jīng)期綜合征患者，使用隨機(jī)數(shù)字表法將其隨機(jī)分成與對(duì)照組和治療組，每組各50例。對(duì)照組口服雌二醇片/雌二醇地屈孕酮片復(fù)合包裝，1片/次，1次/d，以28 d為1個(gè)療程，前14 d服用白色片，后14 d服用灰色片。治療組在對(duì)照組基礎(chǔ)上口服紅花逍遙片，3片/次，3次/d。兩組均連續(xù)治療3個(gè)療程。觀察兩組的臨床療效，比較兩組改良Kupperman絕經(jīng)指數(shù)（KMI）評(píng)分、絕經(jīng)期生存質(zhì)量量表（MENQOL）總分、血流變學(xué)指標(biāo)[全血高、低切黏度（HBV和LBV）、紅細(xì)胞沉降率（ESR）和纖維蛋白原（FIB）]及血清性激素[卵泡刺激素（FSH）、促黃體生成素（LH）和雌二醇（E₂）]、炎癥因子[腫瘤壞死因子（TNF）-α、白細(xì)胞介素（IL）-6]水平的變化情況。結(jié)果 治療后，治療組總有效率為96.0%，顯著高于對(duì)照組84.0%（P<0.05）。與治療前相比，兩組治療后改良KMI評(píng)分和MENQOL總分均顯著降低（P<0.05），且與對(duì)照組治療后相比，治療組對(duì)以上評(píng)分的改善效果更顯著（P<0.05）。兩組治療后HBV、LBV、ESR及FIB均顯著低于本組治療前（P<0.05）；治療后，治療組血流變學(xué)指標(biāo)低于對(duì)照組（P<0.05）。治療后，兩組血清FSH、LH、TNF-α和IL-6水平均較本組治療前顯著下降，但血清E₂水平均顯著升高（P<0.05）；且治療后治療組血清性激素和炎癥因子水平改善更明顯（P<0.05）。結(jié)論 紅花逍遙片聯(lián)合雌二醇片/雌二醇地屈孕酮片復(fù)合包裝治療圍絕經(jīng)期綜合征患者效果確切，能減輕患者圍絕經(jīng)期相關(guān)癥狀、提高生命質(zhì)量，并能顯著改善機(jī)體血液流變學(xué)狀態(tài)、調(diào)節(jié)生殖內(nèi)分泌紊亂及下調(diào)相關(guān)炎癥因子表達(dá)，值得臨床推廣應(yīng)用。

Objective To investigate the clinical effect of Honghua Xiaoyao Tablets combined with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging in treatment of perimenopausal syndrome.Methods A total of 100 patients with perimenopausal syndrome admitted to Xinxiang Central Hospital from July 2016 to June 2019 were selected and randomly divided into control group and treatment group by random number table method, with 50 cases in each group. Patients in the control group were po administered with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging, 1 tablet/time, once daily, 28 days as a course of treatment, the first 14 days to take white tablets, and the last 14 days to take gray tablets. Patients in the treatment group were po administered with Honghua Xiaoyao Tablets on the basis of the control group, 3 tablets/time, 3 times daily. Both groups were treated for 3 courses continuously. The clinical efficacy of the two groups was observed. The modified Kupperman menopausal index (KMI) score, menopausal quality of life scale (MENQOL) total score, hemorheology indexes [whole blood high and low shear viscosity (HBV and LBV), erythrocyte sedimentation rate (ESR) before and after treatment in the two groups), and fibrinogen (FIB)] serum sex hormones [follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E₂)], and inflammatory factors [tumor necrosis factor (TNF)-α, interleukin (IL)-6] were observed.Results The total effective rate of the treatment group was 96.0%, which was significantly higher than that of the control group 84.0% (P<0.05). Compared with before treatment, the modified KMI score and MENQOL total score were significantly decreased in both groups after treatment (P<0.05), and the improvement of the above scores in the treatment group was more significant than that in the control group after treatment (P<0.05). After treatment, HBV, LBV, ESR and FIB in two groups were significantly lower than those before treatment (P<0.05). After treatment, the hemorheological indexes of treatment group were lower than those of control group (P<0.05). After treatment, serum FSH, LH, TNF-α and IL-6 levels in two groups were significantly decreased compared with before treatment, but serum E₂ level was significantly increased (P<0.05). After treatment, the serum levels of sex hormones and inflammatory factors in the treatment group were significantly improved (P<0.05).Conclusion Honghua Xiaoyao Tablets combined with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging has exact effect in treatment of perimenopausal syndrome, and can reduce perimenopausal symptoms, improve the life quality, and can significantly improve the body state of blood rheology, and regulate reproductive endocrine disorders and cut the related inflammation factor expression, which is worthy of clinical popularization and application.

R984

新鄉(xiāng)市科技攻關(guān)計(jì)劃項(xiàng)目（GXGG18038）